# Syngene International Ltd (SYNGENE)
> Exchange: NSE | Sector: Healthcare | ISIN: 

## Price
Current Price: ₹449.5
Day Change: +3.51%
52W High: ₹728.6
52W Low: ₹380
Market Cap: ₹18,716 Cr

## Valuation
P/E: 53.41
P/B: 3.95
EPS: ₹8.72
Book Value: ₹117.84
Dividend Yield: 0.28%

## Returns
1Y Return: -29.73%

## Profitability
ROE: 6.62%
ROCE: 13.65%
Debt/Equity: 0.09
Revenue Growth: 1.8%
Profit Growth: -19.5%
EBITDA Margin: 26.2%
Operating Margin: 20.55%

## About
Syngene International Ltd is a Diagnostics & Research company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Healthcare
Industry: Diagnostics & Research
Sub Industry: Unknown

## Business Model
Overview: Syngene International Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Diagnostics & Research. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Healthcare.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Announcement: Announcement under Regulation 30 (LODR)-Newspaper Publication
- PR Newswire: Syngene strengthens leadership team with two key appointments

## Access
Current tier: anonymous
More history: Register free to see 5 more years.

## Data Freshness
Quote Updated: 2026-06-08T20:00:07.519Z
Price History Updated: 2026-06-08T18:00:31.821Z
Latest Price History Date: 2026-06-08
Technicals Updated: 2026-06-08T18:00:31.821Z
Quant Updated: 2026-06-08T18:00:31.821Z
Sentiment Updated: 2026-06-08T18:00:31.821Z
Financials Status: current
Financials Updated: 2026-05-18T09:30:50.725Z
Financials Last Attempt: 2026-05-18T09:30:50.725Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2019)
Revenue: ₹1423 Cr
Operating Profit: ₹474 Cr (OPM 33%)
Net Profit: ₹305 Cr
Tax: ₹372 Cr

## Annual P&L History
Mar 2019: Rev ₹1423Cr | PAT ₹305Cr | OPM 33%
Mar 2020: Rev ₹1826Cr | PAT ₹332Cr | OPM 29%
Mar 2021: Rev ₹2012Cr | PAT ₹412Cr | OPM 31%

## Balance Sheet (Mar 2019)
Total Assets: ₹3189 Cr
Total Liabilities: ₹3189 Cr
Borrowings: ₹787 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Kiran  Mazumdar-Shaw B.Sc (Hons), B.Sc., Executive Chairperson
- Peter James Jonathan Bains, CEO, MD & Director
- Deepak  Jain, Chief Financial Officer
- Gaurav  Kushwaha, Chief Technology Officer
- Jayashree  Aiyar Ph.D., Chief Scientific Officer

---
Source: rupiya.io/stocks/syngene
Disclaimer: For research and education only. Not investment advice.